生命科学资讯

DOJ urges Supreme Court to undo revival of Hikma ‘skinny label’ case

Doug Ingram’s force of will meets its match as Sarepta CEO plans to depart

FDA probes internal Prasad complaints with outside help

Boehringer wins accelerated approval for first-line use of lung cancer drug

Senate hearing raises FDA-related concerns for new rare disease drugs

Viatris plans to lay off up to 10% of staff, discloses Indian factory fire

Why did my doctor push Grail’s dubious cancer test?

AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug

Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

Salma Health raises $80M for its clinics to treat brain health

OrbiMed jumps to number one on the top 100 list of biotech venture investors

Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects

Japan's Asahi Kasei to buy German biotech Aicuris for $920M

Sarepta CEO Doug Ingram to step down

Gilead, Merck plan to debut new daily HIV pills

Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug

Charles River sells its CDMO and European discovery businesses

Accent axes a cancer study; Werewolf considers its options

Alkermes CEO Richard Pops to retire after 35-year tenure